Navigation Links
OCT Clinical Trials Successfully Recruits 700 Patients for Phase III Erectile Dysfunction Study
Date:8/16/2019

OCT Clinical Trials, the leading CRO in Russia and Eastern Europe since 2005, announced it has successfully completed enrollment of 690 patients for a phase III efficacy study of a drug for male erectile dysfunction. This is a dose ranging, multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which is a topical gel developed by UK-based pharmaceutical company Futura Medical.

The study’s participants are males aged 18 to 70 undergoing a 12-week treatment with three active variations of dosage. The effects of long-term treatment (up to 12 months) will be evaluated as well in an open label extension phase (OLE). Recruitment started in October 2018 and the last patient was screened in June 2019. Over one thousand patients were randomized into the study within nine months with a screen failure rate of only nine percent, which was in line with initial projections and sponsor's expectations.

The phase III study of MED2002 is now ongoing in nine European countries. OCT is overseeing all major activities in four of them, with 20 sites in Russia, five in Bulgaria, eight in Ukraine and three in Latvia. Sixty-nine percent of all patients were recruited by OCT in four countries, while another CRO enrolled 315 patients in six other countries.

Successful enrollment for this study was due to OCT’s in-depth feasibility analysis and thorough study planning, as well as high professionalism of experienced CRAs who demonstrated excellent ability to work collaboratively with sites, swiftly resolving any issues that arose during the study. In addition, OCT’s local expertise in Russia helped clarify several key issues for the sponsor regarding logistical and regulatory matters.

Headline data for the study is planned to be made available by the end of 2019.

About Futura Medical
Futura Medical is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology. These products are optimized for clinical efficacy, safety, administration and patient convenience and are developed for the prescription and consumer healthcare markets as appropriate. Current therapeutic areas are sexual health, including erectile dysfunction, and pain relief. Development and commercialization strategies are designed to maximize product differentiation and value creation whilst minimizing risk. Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange. Learn more at http://www.FuturaMedical.com.

About OCT Clinical Trials
OCT Clinical Trials is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT’s experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at http://www.OCT-ClinicalTrials.com.

Read the full story at https://www.prweb.com/releases/oct_clinical_trials_successfully_recruits_700_patients_for_phase_iii_erectile_dysfunction_study/prweb16505766.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related medicine technology :

1. More Than a Second Opinion: The GCS Project and InfiniteMD’s Expert Access Program has Helped Individuals Navigate Cancer Treatment Centers and Available Clinical Trials
2. Iqbal Husain’s new book “Homeopathy in Practice: Clinical Insights into Homeopathy & Remedies, Volume 1” offers clinical keynotes on remedies for various illnesses
3. eClinical Provider, Crucial Data Solutions, Names Jeff Rogers as President
4. Circularity Enters Talks to Close Institutional Financing Round, Announces Phase 3 Clinical Research & Human Trials of Diabetic Foot Ulcer Treatment and Microcirculation
5. AngelEye Health Announces New Clinical Advisor
6. New Clinical Trial - Natreon’s PrimaVie® Shilajit Ingredient Showed Results of Improved Skin Health in Adult Women
7. HHHRA
8. HR Maximizer Annual Healthcare Provider & Clinical Staff Conference Announces Platinum Sponsor and Topics List
9. AskBio's Perspective on Pfizer's 1b Clinical Trial Results on Duchenne MD Gene Therapy
10. The Conference Forum Announces Disruptive Innovations in Clinical Trials Event (DPharm) 2019 Keynotes
11. ERT Showcases Scientific and Technological Expertise in Improving Clinical Research at DIA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... CLARA, Calif. (PRWEB) , ... September 01, 2020 ... ... and analytical laboratory technologies, will host the Agilent Science and Technology Virtual ... During this two-day symposium, Agilent will open a suite of Live webinars and ...
(Date:9/1/2020)... ... , ... While coronavirus cases continue to increase across the country, blood drives ... closed. Because about 80% of blood donations are made at drives hosted by these ... drive hosts to ensure blood products are readily available for patients. , Those ...
(Date:8/31/2020)... ... August 31, 2020 , ... Welltech1, the first Israeli VC ... invested $400,000 in PopBase, one of two start-ups that beat 152 companies in ... (GWI). , The competition was part of the GWI’s The Wellness Moonshot: ...
Breaking Medicine Technology:
(Date:8/31/2020)... , ... August 31, 2020 , ... Just found out your dear friend has cancer? ... when your friend or family member shares their diagnosis. Once the shock wears off, the ... the wrong thing? What are the best ways to help? Words are failing me. I’m ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University Global ... and affordable online education – is proud to announce its new master’s degree ... of its kind in the nation, the 60-credit hour program is designed to ...
(Date:8/31/2020)... ... 31, 2020 , ... In an effort to give back to the community ... of each hotel room booked with a special new rate code to benefit children ... , effective immediately. Donations will be applied to any room type, any time, ...
(Date:8/28/2020)... ... 2020 , ... Ernst & Young LLP (EY US) today ... The Year® 2020 Florida Award finalist. Now in its 34th year, the Entrepreneur ... and prosperity as they build and sustain successful businesses that transform our world. ...
(Date:8/28/2020)... ... ... Integrated Viral Protection (IVP Air) today announced that the True North ... Biodefense Indoor Air Protection System that is the first system designed and proven to ... with the filtration system on September 8th. , The IVP Air S1 model ...
Breaking Medicine News(10 mins):